Enliven Therapeutics Inc 2026年季度报告

(Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _________ to _________Commission File Number: 001-39247 ENLIVEN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Registrant’s telephone number, including area code: (720) 647-8519 Not applicable (Former name, former address, and formerfiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) hasfiled all reports required to befiled by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required tofile such reports), and (2)has been subject to suchfiling requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuantto Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit suchfiles).Yes☒No☐ Indicate by check mark whether the registrant is a large acceleratedfiler, an acceleratedfiler, a non-acceleratedfiler, a smaller reportingcompany, or an emerging growth company. See the definitions of “large acceleratedfiler,” “acceleratedfiler,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large acceleratedfiler☐Non-acceleratedfiler☒Emerging growth company☐ Acceleratedfiler☐Smaller reporting company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of April 28, 2026, the registrant had 60,904,946 shares of common stock, $0.001 par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATIONItem 1.Condensed Consolidated Financial Statements (Unaudited)3Condensed Consolidated Balance Sheets3Condensed Consolidated Statements of Operations and Comprehensive Loss4Condensed Consolidated Statements of Stockholders’ Equity5Condensed Consolidated Statements of Cash Flows6Notes to Unaudited Condensed Consolidated Financial Statements7Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations24Item 3.Quantitative and Qualitative Disclosures About Market Risk33Item 4.Controls and Procedures34 PART II.OTHER INFORMATIONItem 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSIGNATURES SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This quarterly report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. Allstatements other than statements of historical facts contained in this quarterly report on Form 10-Q, including statements regardingour future results of operations andfinancial position, business strategy, development plans, planned preclinical studies and clinicaltrials, future results of clinical trials, expected research and development costs, regulatory strategy, timing and likelihood of success,as well as plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identifyforward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,”“target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or othersimilar expressions. Forward-looking statements contained in this quarterly report on Form 10-Q include, but are not limited to,statements about: •the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;•the timing, progress and results of clinical trials for ELVN-001 from our BCR-ABL (as defined below) program and otherproduct candidates we have and may in the future develop, including statements regarding the timing of initiation andcompletion of studies or trials and related preparatory work, the period during which the results of the studies or trials willbecome available, and research and development programs;•the potential of, and plans regarding, market opportunities, and expectations regarding our programs, including ELVN-001;•the timing, scope and likelihood of regulatoryfilings and approvals, including timing of investigational new drug applications(